Interdisciplinary Bio Central
 
Hypothesis/Idea (Pharmaceutical bioscience and technology)

Cholesterol, Statins, and Brain Function: A Hypothesis from a Molecular Perspective
Yeon-Kyun Shin1,*
1Integrative Bioscience and Biotechnology, POSTECH, Pohang, Korea 790-784, and Department of Biochemistry, Biophysics, and Molecular Biology, Iowa State University, Ames, IA 50014
*Corresponding author
  Received : March 24, 2009
  Accepted : March 27, 2009
  Published : March 30, 2009
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Main text PDF(2646KB)
   (Print version)
Synopsis

There is evidence that cholesterol in the brain plays an important role in the neurotransmitter release. A decrease of the cholesterol level severely hampers the activity of the membrane fusion machinery, thereby inhibiting the release. Meanwhile, the results from several clinical studies suggest that a low cholesterol level is linked to the dysfunction of some brain activities. Because the neurotransmitter release underlies the basic brain function, the combined results lead to a testable hypothesis that the cholesterol-lowering drugs may inhibit the neurotransmitter release at the synapse. Such inhibition of the release could result in impaired brain function for a limited group of people. A molecular basis for the hypothesis is discussed.

Keyword: Neurotransmitter release, SNARE, membrane fusion, synapse, raft
IBC   ISSN : 2005-8543   Contact IBC